Lucid Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Lucid Diagnostics
LUCD Stock  USD 0.98  0.01  1.01%   
Lucid Diagnostics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lucid Diagnostics' valuation are provided below:
Gross Profit
-2.8 M
Market Capitalization
107.1 M
Enterprise Value Revenue
41.1102
Revenue
4.2 M
Earnings Share
(1.17)
There are over one hundred nineteen available fundamental ratios for Lucid Diagnostics, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Lucid Diagnostics' last-minute performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of August 8, 2025, Market Cap is expected to decline to about 39.3 M. In addition to that, Enterprise Value is expected to decline to about 38.2 M

Lucid Diagnostics Total Revenue

4.56 Million

Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 24.7 K or Selling General Administrative of 12.7 M, as well as many indicators such as Price To Sales Ratio of 9.04, Dividend Yield of 0.0 or PTB Ratio of 0.0081. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
  
Build AI portfolio with Lucid Stock
Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Lucid Diagnostics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets24 M30.7 M11.1 M
Slightly volatile
Other Current Liabilities2.2 M2.3 M3.2 M
Slightly volatile
Total Current Liabilities13.9 M23.5 M7 M
Slightly volatile
Other Liabilities288.3 K324.4 K353.7 K
Slightly volatile
Accounts Payable1.3 M1.2 M848 K
Slightly volatile
Cash18.5 M22.4 M8.5 M
Slightly volatile
Cash And Short Term Investments23.5 B22.4 B2.9 B
Slightly volatile
Common Stock Shares Outstanding43.3 M50.5 M38.4 M
Slightly volatile
Liabilities And Stockholders Equity24 M30.7 M11.1 M
Slightly volatile
Other Stockholder Equity219.7 B209.3 B26.8 B
Slightly volatile
Total Liabilities14.4 M25.3 M7.2 M
Slightly volatile
Total Current Assets26.4 B25.1 B3.2 B
Slightly volatile
Common Stock34.4 K63 K20.9 K
Slightly volatile
Non Current Assets Total4 M5.6 M2 M
Slightly volatile
Non Currrent Assets Other1 M1.3 M778.7 K
Slightly volatile
Short Term Investments1.6 M1.5 M513.4 K
Slightly volatile
Non Current Liabilities Total1.7 M1.8 M174 M
Pretty Stable
Other Current Assets2.5 B2.4 B308.6 M
Slightly volatile
Capital Stock57.2 M54.5 M8.2 M
Slightly volatile
Net Receivables425.2 K405 K68.3 K
Slightly volatile
Property Plant Equipment1.4 M1.8 M1.1 M
Slightly volatile
Short and Long Term Debt Total14.1 M21.3 M4.8 M
Slightly volatile
Common Stock Total Equity32.8 K36.9 K40.2 K
Slightly volatile
Capital Surpluse96.9 M109 M118.8 M
Slightly volatile
Non Current Liabilities Other829.6 K933.3 K1 M
Slightly volatile
Short Term Debt13 M19.5 M3.8 M
Slightly volatile
Intangible Assets699.2 K736 K3 M
Slightly volatile
Current Deferred Revenue748.8 K842.4 K918.5 K
Slightly volatile
Short and Long Term Debt17.9 M18.6 M14.5 M
Slightly volatile
Good Will588.2 M661.7 M721.5 M
Slightly volatile

Lucid Diagnostics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.3 M1.2 M2.2 M
Pretty Stable
Selling General Administrative12.7 M20.2 M6.1 M
Slightly volatile
Selling And Marketing Expenses10.2 M16.5 M4.3 M
Slightly volatile
Other Operating Expenses31.5 M50.4 M15.3 M
Slightly volatile
Research Development6.9 M6 M3.5 M
Slightly volatile
Total Operating Expenses28.1 M42.1 M13.5 M
Slightly volatile
Interest Income305.8 K322 K137.2 K
Slightly volatile

Lucid Diagnostics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings9.3 M8.9 M3.2 M
Slightly volatile
Stock Based Compensation5.7 M4.5 M2.7 M
Slightly volatile
Other Cashflows From Financing Activities31.8 M30.2 M5.8 M
Slightly volatile
Depreciation882.8 K1.2 M408.3 K
Slightly volatile
Capital Expenditures596.9 K646 K794.7 K
Slightly volatile
Change To Operating Activities11.1 M10.5 M3 M
Slightly volatile
Total Cash From Financing Activities25.2 M48.2 M11.7 M
Slightly volatile
End Period Cash Flow18.5 M22.4 M8.5 M
Slightly volatile
Change To Netincome16.7 M15.9 M4.6 M
Slightly volatile
Begin Period Cash Flow17.5 M18.9 M7.1 M
Slightly volatile
Sale Purchase Of Stock405.9 M447 M176.3 M
Slightly volatile
Change Receivables146.4 K164.7 K179.6 K
Slightly volatile
Cash Flows Other Operating2.4 M2.7 M2.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.049.5162292
Slightly volatile
Days Sales Outstanding35.7134.01418.1534
Slightly volatile
Average Payables1.1 M1.3 M1.4 M
Slightly volatile
Stock Based Compensation To Revenue0.991.043317.1864
Slightly volatile
Capex To Depreciation0.530.5536162
Slightly volatile
EV To Sales8.89.2621208
Slightly volatile
Inventory Turnover17.0120.81827.1952
Slightly volatile
Days Of Inventory On Hand16.6617.5328234
Slightly volatile
Payables Turnover3.385.72041.5395
Slightly volatile
Sales General And Administrative To Revenue4.414.637824.1547
Pretty Stable
Average Inventory432.1 K597 K475.3 K
Slightly volatile
Research And Ddevelopement To Revenue1.311.378716.1996
Slightly volatile
Capex To Revenue0.140.14861.4673
Slightly volatile
Cash Per Share0.360.44260.2187
Slightly volatile
Days Payables Outstanding60.6263.8069715
Slightly volatile
Income Quality1.020.96950.3683
Slightly volatile
Intangibles To Total Assets0.02280.0240.0923
Slightly volatile
Current Ratio1.1 K1.1 K138
Slightly volatile
Receivables Turnover17.8710.73098.4208
Slightly volatile
Capex Per Share0.01870.01280.0224
Slightly volatile
Revenue Per Share0.09030.0860.026
Slightly volatile
Interest Debt Per Share0.440.42130.0949
Slightly volatile
Debt To Assets0.350.6920.15
Slightly volatile
Operating Cycle48.9751.5468349
Slightly volatile
Days Of Payables Outstanding60.6263.8069715
Slightly volatile
Ebt Per Ebit0.820.98861.0033
Very volatile
Total Debt To Capitalization0.00370.00390.139
Pretty Stable
Quick Ratio1.1 K1.1 K138
Slightly volatile
Net Income Per E B T0.820.921.0043
Slightly volatile
Cash Ratio0.90.95041.121
Slightly volatile
Days Of Inventory Outstanding16.6617.5328234
Slightly volatile
Days Of Sales Outstanding35.7134.01418.1534
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.01461.048
Very volatile
Fixed Asset Turnover1.231.17490.6005
Slightly volatile
Debt Ratio0.350.6920.15
Slightly volatile
Price Sales Ratio9.049.5162292
Slightly volatile
Asset Turnover0.150.14150.0309
Slightly volatile

Lucid Diagnostics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap39.3 M41.4 M322.6 M
Slightly volatile
Enterprise Value38.2 M40.3 M317.6 M
Slightly volatile

Lucid Fundamental Market Drivers

Cash And Short Term Investments22.4 B

Lucid Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lucid Diagnostics Financial Statements

Lucid Diagnostics stakeholders use historical fundamental indicators, such as Lucid Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lucid Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lucid Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue842.4 K748.8 K
Total Revenue4.3 M4.6 M
Cost Of Revenue7.1 M4.4 M
Stock Based Compensation To Revenue 1.04  0.99 
Sales General And Administrative To Revenue 4.64  4.41 
Research And Ddevelopement To Revenue 1.38  1.31 
Capex To Revenue 0.15  0.14 
Revenue Per Share 0.09  0.09 
Ebit Per Revenue(10.60)(11.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
How To Invest In Lucid
Details
Is Lucid Stock a good investment?
Details
What is Lucid Diagnostics' Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Revenue Per Share
0.074
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.92)
Return On Equity
(18.97)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY